Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inositol and Omega-3 in Pediatric Mania
NCT01396486Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2012
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of omega-3 fatty acid and bCalm in bipolar spectrum disorder (BSD) (3 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Young Mania Rating Scale at 12 weeks and Children's Depression Rating Scale at 12 weeks. Started Feb 2012; status: completed.
02
Drugs
omega-3 fatty acidbCalm
03
Conditions
bipolar spectrum disorder (BSD)
Beyond the preview
Go deeper on NCT01396486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01396486.